CureDuchenne welcomes Patricia Brown to executive team

CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy and based in Newport Beach, announced an addition to its executive team with the hiring of Senior Director of Community Engagement Patricia Brown, MBA, BSN, R.N. This position plays a crucial role in CureDuchenne’s mission of improving the lives of individuals and families affected by Duchenne muscular dystrophy, championing the needs of the community and fostering relationships with external partners, caretakers and healthcare providers.

Click on photo for a larger image

Courtesy of CureDuchenne

Patricia Brown

Brown will be focused on growing CureDuchenne’s presence and building clinic relationships in Newport Beach and the surrounding area. She will help the organization foster relationships with external partners, caretakers and healthcare providers in the community to improve the lives of individuals and families affected by Duchenne muscular dystrophy. The Newport Beach community plays a critical role in supporting CureDuchenne’s efforts to find a cure for Duchenne muscular dystrophy through events like the upcoming 10th anniversary of the Napa in Newport fundraiser being held on Saturday April 20 at The Pendry in Newport Beach. More information on tickets and sponsorships can be found at www.thenapawineseries.com/napa-in-newport/.

A seasoned professional with more than 15 years of experience in healthcare, Brown has deep experience in advocacy, community education and patient care. Most recently serving as associate director of Patient Engagement North America at PTC Therapeutics, she excelled in supporting individuals with Duchenne muscular dystrophy and their caregivers. Her work involved understanding the needs and challenges of the community and leading cross-functional collaboration to identify and implement effective solutions for addressing disparities in care. She also brings expertise in working with patient advocacy organizations to facilitate patient access to resources such as external appeal assistance, family support and community networking. Prior to PTC Therapeutics, Brown served as a senior nurse manager at Lash Group, where she designed and deployed pharmaceutical clinical support services for FDA-approved medications and led educational programs tailored to address emerging trends observed within the community. Brown received her Master of Business Administration degree from Texas Women’s University and Bachelor of Science degree in nursing from Texas Tech University.

“Patricia Brown joining our team reinforces our commitment to not just finding a cure, but also to enhancing the quality of life for those affected by Duchenne muscular dystrophy,” said CureDuchenne founder and CEO Debra Miller. “Patricia’s deep understanding of patient needs and challenges, coupled with her experience in fostering collaborative solutions, will be instrumental in advancing our mission. We look forward to the positive changes and new perspectives Patricia will bring to CureDuchenne.”

CureDuchenne was founded by Debra and Paul Miller in 2003 after their son was diagnosed with Duchenne muscular dystrophy. The organization combines fundraising and venture philanthropy, identifying and investing donor dollars into promising research leading to transformative treatments for those living with Duchenne. CureDuchenne also provides resources and guidance for families affected by the fatal genetic neuromuscular disorder, which affects more than 300,000 individuals worldwide.

For more information, visit https://cureduchenne.org.

Send this to a friend